Guggenheim analyst Vamil Divan raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $115 from $114 and keeps a Buy rating on the shares. The firm is updating its model after the company reported “yet another beat and raise quarter” and following its follow-up conversation with management.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals’ Earnings Call Highlights Record Growth
- ANI Pharmaceuticals Reports Record Q3 2025 Results
- ANI Pharmaceuticals: Strong Commercial Execution and Promising Growth Prospects Reinforce Buy Rating
- ANI Pharmaceuticals raises FY25 adj. EPS view to $7.37-$7.64 from $6.98-$7.35
- ANI Pharmaceuticals reports Q3 adjusted EPS $2.04, consensus $1.77